Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
The NHS Commissioning Board (Operating Under the Name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: katie.noonan@nhs.net
NUTS: UK
Internet address(es)
Main address: https://nhsengland.bravosolution.co.uk
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Framework Agreement for Branded Medicines — National
Reference number: CM/PHR/16/5518
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS Framework Agreement for Branded Medicines – National.
Contract period: 1.5.2019 to 30.4.2021 (with an option to extend for a period or periods of up 24 months).
Tender Reference: CM/PHR/18/5518.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
2 956 000 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKC
UKD
UKE
UKF
UKG
UKH
UKI
UKJ
UKK
Main site or place of performance:
Please refer to Schedule 8, Document No 3.
II.2.4) Description of the procurement
Products associated with the lots are listed on document No 05a of the invitation to offer. Each individual National Product Code (NPC) pack description in England is deemed to be a separate product for the application of the award criteria. Please refer to Schedule 8, Document No 3 which includes a link to the purchasing points. There is no restriction on the number of products that bidders can offer for, or be awarded.
The Framework Agreement is intended for use by the Department of Health, Public Health England and NHS England and NHS Improvement. The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: n/a
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: n/a
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2018/S 240-547799
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
18/04/2019
V.2.2) Information about tenders
Number of tenders received: 87
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
NHS Comissioning Boards (Operating under the name of NHS England)
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 2 956 000 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded suppliers:
— AbbVie Ltd,
— Accord-UK Ltd,
— Acre Pharma Ltd,
— Aguettant Ltd,
— Alissa Healthcare Research Ltd,
— Alliance Pharmaceuticals Ltd,
— Almirall Ltd,
— Aspen Pharma Ireland Ltd,
— Aspire Pharma Ltd,
— Astellas Pharma Ltd,
— AstraZeneca UK,
— Aventis Pharma Ltd Trading as Sanofi,
— B. Braun Medical Ltd,
— Bayer Plc,
— Beaver Visitec International Sales Ltd,
— Biofrontera Pharma GmbH,
— Biogen Idec Ltd,
— Bristol-Myers Squibb Pharmaceuticals Ltd,
— CCMed Ltd,
— Chiesi Ltd,
— Cipla (EU) Ltd,
— Consilient Health,
— Crescent Pharma Ltd,
— Desitin Pharma Ltd,
— Dexcel Pharma Ltd,
— Dr Falk Pharma UK Ltd,
— DRUGSRUS Ltd,
— Eisai Ltd,
— Eli Lilly and Company Ltd,
— Ennogen Healthcare Ltd,
— Fannin UK Ltd TA Kent Pharmaceuticals Ltd,
— Ferndale Pharmaceuticals Ltd,
— Ferring Dhaliwal,
— Flynn Pharma Ltd,
— Focus Pharmaceuticals Ltd,
— Gedeon Richter (UK) Ltd,
— Gilead Sciences Ltd,
— Glenmark Pharmaceuticals Europe Ltd,
— GSK UK Ltd,
— Intrapharm Laboratories Ltd,
— Ipsen Ltd,
— Janssen Cilag Ltd,
— Kyowa Kirin Ltd,
— Lupin Healthcare (UK) Ltd,
— Martindale Pharma,
— medac Pharma LLP,
— Merck Serono,
— Mercury Pharmaceuticals Ltd,
— Morningside Pharmaceuticals Ltd,
— Mylan,
— Napp Pharmaceuticals Ltd,
— Neon Healthcare Ltd,
— Nordic Pharma Ltd,
— Norgine Pharmaceuticals Ltd,
— Novartis Pharmaceuticals UK Ltd,
— Novo Nordisk Ltd,
— Genzyme Therapeutics Ltd,
— Parapharm Development Ltd,
— Pfizer Ltd,
— Pharmacosmos UK,
— Rayner Pharmaceuticals Ltd,
— RB UK Healthcare UK,
— Roche Products Ltd,
— Rosemont Pharmaceuticals Ltd,
— Sandoz Ltd,
— Selective Supplies,
— Takeda UK Ltd,
— Teva UK Ltd,
— Thea Pharmaceuticals Ltd,
— Thornton and Ross,
— Tillomed Laboratories Ltd,
— Tillotts Pharma UK Ltd,
— Torrent Pharma UK Ltd,
— Typharm Ltd,
— UCB Pharma Ltd,
— Zentiva Pharma UK Ltd.
VI.4) Procedures for review
VI.4.1) Review body
The Royal Courts of Justice
London or any of the district registry of the High Court
UK
VI.5) Date of dispatch of this notice
14/06/2019